Clinical Trial Update: Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reports safety and efficacy results for Tenalisib (RP6530) in combination with Romidepsin in relapsed/refractory T-cell lymphoma (Phase 1/…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma
• T-cell Lymphoma
• T-cell Lymphoma Not Otherwise Specified

Drugs mentioned

• Romidepsin (romidepsin)
• Tenalisib (RP6530) (RP6530)

Snippet

Sponsor: Rhizen Pharmaceuticals SA | Conditions: T Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-10-28